• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Displaying 129-143 of 2,314 results

No. 124 DECLARATION of John P. Bueker in support NOTICE OF MOTION AND MOTION to Dismiss First Amended ...

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 124 (C.D.Cal. Dec. 13, 2023)
I am admitted pro hac vice to practice before this Court and am a partner at the law firm Ropes & Gray LLP, counsel of record for Defendants Genzyme Corporation, Sanofi-Aventis U.S. LLC, and Sanofi US Services Inc. in this action.
Exhibit 14 hereto is a true and correct copy of written congressional testimony of Stuart Wright, Deputy Inspector General for Evaluation and Inspections, before the House Committee on Energy and Commerce Subcommittee on Oversight and Investigations dated December 15, 2005, available at https://oig.hhs.gov/documents/testimony/88/20051215_-_Wright.pdf.
Exhibit 15 hereto is a true and correct excerpt of the record of a hearing before the House Energy and Commerce Committee Subcommittee on Health titled “Examining the 340B Drug Pricing Program,” held March 24, 2015, available at https://www.congress.gov/event/114th-congress/house-event/103082/text.
Exhibit 17 hereto is a true and correct excerpt of a U.S. Senate Finance Committee report titled “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug,” dated January 14, 2021, available at https://www.finance.senate.gov/imo/media/doc/Insulin%20Committee%20Print.pdf.
Exhibit 23 hereto is a true and correct copy of an article from BNA titled “California County Sues Drug Manufacturers, Alleges Firms Overcharge Public Agencies,” dated September 9, 2005.
cite Cite Document

No. 120 MOTION RE: INFORMAL DISCOVERY DISPUTE

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 120 (C.D.Cal. Dec. 8, 2023)
Counsel for each party has submitted their respective positions and the issue will be adjudicated in accordance with the Magistrate Judge's procedures.
Discovery will likely be broad in scope and impose substantial burdens on Defendants, the United States government and potentially the Court.
Depending on the Court's decision on the MTD, Relator could seek leave to amend again, which could also change the scope of the case and of discovery.
Relator's complaint alleges a straightforward scheme that is capable of proof by a discrete set of data and communications.
Nevertheless, in the interest of limiting the burden on Defendants at this early stage of the case, Relator proposed that each Defendant create an index of any communications with and/or documents produced to government entities (e.g., CMS, state Medicaid agencies, etc.) relating to the 340B ceiling prices of the drugs at issue in the complaint.
cite Cite Document

No. 54 PROOF OF SERVICE Executed by Plaintiff Adventist Health System West, upon Defendant Novartis ...

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 54 (C.D.Cal. Aug. 14, 2023)
Case 2:21-cv-04249-DSF-SK Document 54 Filed 08/14/23 Page1of1 Page ID #:468 AO 440 (Rev.
P. 4 ()) This summonsfor (name ofindividual andtitle, ifany) NOVARTIS PHARMACEUTICALS CORPORATIONwas
[xX] on (date) ,a , and mailed a copy to [] I personally served the summonsonthe individual at (place) 5 or I left the summonsat the individual’s residence or usual place of abode with (name) person of suitable age and discretion whoresides there, on (date) the individual's last known address; or I served the summons on (nameofindividual) Lisa Constant, Customer Service for Corporation Service Company as Registered Agent for NOVARTIS PHARMACEUTICALS CORPORATION, whois designated by law to accept service of process on behalf of (name oforganization) NOVARTIS PHARMACEUTICALS CORPORATIONon (date) Mon, Jul 31 2023 at 8:39 am EDT; or I returned the summonsunexecuted because:
Myfees are $ for travel and $ for services, for a total of $ I declare under penalty of perjury that this informationis true.
Date: 9 2{ 23 GREGORY DUKE,Process Server Printed nameandtitle ABCProcess Service, 4834 Swiss Avenue, Dallas, TX 75204 Server's address Additional information regarding attempted service, etc.: 1) Successful Attempt: Jul 31, 2023, 8:39 am EDT at Corporation Service Company, 100 Charles Ewing Blvd, Ewing, NJ 08628 received by Lisa Constant, Customer Service for Corporation Service Company as Registered Agent for NOVARTIS
cite Cite Document

No. 42 UNITED STATES' APPLICATION FOR PARTIAL UNSEALING (bm) Modified on 5/2/2023 (bm)

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 42 (C.D.Cal. May. 2, 2023)
The United States hereby files this application for partial unsealing of this matter, pursuant to Local Rule 79-7.2.
In that notice, the United States indicated that the parties subsequently would file a joint stipulation requesting the partial unsealing of this action; or, the United States would file an application requesting the partial unsealing of this action The United States requests that the relator's Complaint, the Notice of Election to Decline Intervention, this Application, and the attached proposed Order be unsealed.
The United States requests that all other papers on file in this action remain under seal because in discussing the content and extent of the United States' investigation, such papers are provided by law to the Court alone for the sole purpose of evaluating whether the seal and time for making an election to intervene should be extended.
Assistant United States Attorney Chief, Civil Fraud Section
On April 28, 2023, I served the UNITED STATES’ APPLICATION FOR PARTIAL UNSEALING OF THIS ACTION on each person or entity named below by e-mail.
cite Cite Document

No. 1

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 1 (C.D.Cal. May. 21, 2021)

cite Cite Document

No. 129 Joint STIPULATION to Continue The Deadline To Conduct The Parties' Rule 26(f) Conference from ...

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 129 (C.D.Cal. Jan. 16, 2024)
Motion to Continue
600 New Hampshire Ave. NW, 10th Floor Washington, DC 20037 Telephone: 202.333.4562 Facsimile: 214.523.6600 *admitted only in California Attorney for Plaintiff-Relator Additional Counsel Listed on Signature Block
ADVENTIST HEALTH SYSTEM/WEST, and on behalf of the STATES of CALIFORNIA,
WHEREAS, on October 12, 2023, the Court entered an Order re: Briefing and Hearing Schedule for Relator’s Amended Complaint and Defendants’ Motion(s) to Dismiss Relator’s Amended Complaint, which set the scheduling conference for February 12, 2024 (Dkt. 104); WHEREAS, on November 7, 2023, Relator Adventist Health System/West (“Relator”) filed a First Amended Complaint (“FAC”); WHEREAS, on December 13, 2023, Defendants AbbVie Inc., Allergan Sales, LLC, Allergan USA, Inc., AstraZeneca LP, AstraZeneca Pharmaceuticals LP, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sandoz Inc., Sanofi US Services Inc., and Sanofi-Aventis U.S. LLC (collectively, “Defendants”) filed motions to dismiss Relator’s FAC; WHEREAS, on December 22, 2023, the parties filed a Notice of Motion and Joint Stipulation of the Parties Pursuant to Local Rule 37-2.1 Regarding Defendants’ Motion to Stay Discovery (“the Motion”); WHEREAS, the current deadline for the parties to conduct the Rule 26(f) conference is January 22, 2024; WHEREAS, on that same date, January 22, 2024, a hearing is set regarding the Motion; WHEREAS, the parties agree that conducting the Rule 26(f) conference will be more efficient after the Court has decided the Motion; WHEREAS, if the Motion is granted, the need for a Rule 26(f) conference is mooted subject to further notice from the Court; WHEREAS, subject to the Court’s approval, the parties hereby stipulate to the following deadlines for holding the Rule 26(f) conference: • If the Court denies the Motion, the parties are to conduct the Rule 26(f) conference within 7 days of the Court’s ruling; and • If the Court grants the Motion, the parties are not required to conduct the Rule 26(f) conference until further notice from the Court.
1501 M Street NW, 7th Floor Washington, DC 20005 Telephone: 202.872.6765 Facsimile: 202.785.1756 *admitted only in California Attorneys for Plaintiff-Relator
5-4.3.4(a)(2)(i), I, Kenneth D. Capesius, attest that all signatories identified above, and on whose behalf the filing is submitted, concur in the filing’s content and have authorized the filing.
cite Cite Document

No. 149

Document United States of America et al v. AbbVie Inc. et al, 2:21-cv-04249, No. 149 (C.D.Cal. Mar. 13, 2024)

cite Cite Document

No. 1

Document Grimsley v. Nike, Inc. et al, 1:24-cv-05986, No. 1 (E.D.N.Y. Aug. 21, 2024)

cite Cite Document

Order Appointing Court Approved Reporter

Document INCRETIN-BASED THERAPY CASES, JCCP4574, Order Appointing Court Approved Reporter (Los Angeles Sup. Ct Nov. 21, 2022)

cite Cite Document

Order Appointing Court Approved Reporter

Document INCRETIN-BASED THERAPY CASES, JCCP4574, Order Appointing Court Approved Reporter (Los Angeles Sup. Ct Nov. 21, 2022)

cite Cite Document

No. 154

Document STATE OF MINNESOTA, BY ITS ATTORNEY GENERAL KEITH ELLISON v. SANOFI-AVENTIS U.S. LLC et al, 2:18-cv-14999, No. 154 (D.N.J. Nov. 15, 2022)

cite Cite Document

McClamrock v. Eli Lilly and Co.

Docket 11-4721, U.S. Court of Appeals, Second Circuit

cite Cite Docket

No. 152

Document STATE OF MINNESOTA, BY ITS ATTORNEY GENERAL KEITH ELLISON v. SANOFI-AVENTIS U.S. LLC et al, 2:18-cv-14999, No. 152 (D.N.J. Sep. 27, 2022)

cite Cite Document

Minute Order MINUTE ORDER

Document INCRETIN-BASED THERAPY CASES, JCCP4574, Minute Order MINUTE ORDER (Los Angeles Sup. Ct Sep. 13, 2022)

cite Cite Document

Minute Order MINUTE ORDER

Document INCRETIN-BASED THERAPY CASES, JCCP4574, Minute Order MINUTE ORDER (Los Angeles Sup. Ct Aug. 31, 2022)

cite Cite Document
<< 1 2 3 4 5 ... 9 10 11 12 13 ... >>